Literature DB >> 20357450

Subtype classification of hepatocellular adenoma.

Paulette Bioulac-Sage1, Charles Balabaud, Jessica Zucman-Rossi.   

Abstract

Hepatocellular adenomas (HCA) are rare benign tumours occurring mainly in women under oral contraceptives. HCA bleed frequently and transform rarely into hepatocellular carcinoma. Identification of genes recurrently mutated in HCA and good genotype/phenotype correlations provided the basis of a pathomolecular classification of different HCA subgroups, characterized using immunohistochemical markers. HNF1A-mutated HCA: Biallelic-inactivating mutations of HNF1A gene are identified in 35-40% of HCA. HNF1alpha-inactivated HCA display characteristic pathological features, including marked steatosis. The expression of FABP1 (which is a HNF1A target gene) is downregulated and the absence of L-FABP expression diagnosed this subgroup. beta-Catenin-mutated HCA: beta-catenin mutations leading to activation of the Wnt/beta-catenin pathway represented 10-15% of HCA. They are characterized by overexpression of glutamine synthetase and aberrant nuclear beta-catenin staining. These beta-catenin-activated HCA are at greater risk of malignant transformation; they are difficult to differentiate from well-differentiated HCC. Inflammatory HCA (50%): These are defined by the presence of inflammatory infiltrates, sinusoidal dilatation and thick-walled arteries. Small in-frame deletions that target the binding site of gp130 for IL-6 have been reported in 60% of inflammatory HCA. There is an overexpression of the inflammatory proteins serum amyloid A and C-reactive protein in tumour hepatocytes both at mRNA and protein levels. Inflammatory HCA occurred more frequently in patients with high body mass index; they can be also mutated for beta-catenin and therefore are probably at risk of HCC. Unclassified HCA: Less than 10% of HCA do not express any of the above-mentioned phenotypic markers. Taking into account noticeable differences between the HCA subgroups, in terms of clinical and prognostic features, phenotyping may become an important tool for HCA management strategy. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20357450     DOI: 10.1159/000268406

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  38 in total

Review 1.  Focal nodular hyperplasia and hepatic adenoma: current diagnosis and management.

Authors:  Agustin Cristiano; Agustin Dietrich; Juan Carlos Spina; Victoria Ardiles; Eduardo de Santibañes
Journal:  Updates Surg       Date:  2013-06-27

Review 2.  Benign liver lesions: grey-scale and contrast-enhanced ultrasound appearances.

Authors:  A E Obaro; S M Ryan
Journal:  Ultrasound       Date:  2015-03-12

Review 3.  Gd-EOB-DTPA-Enhanced Magnetic Resonance Findings of a Giant Inflammatory Hepatocellular Adenoma: a Case Report and Review of the Literature.

Authors:  Marco Di Pietropaolo; Chiara Briani; Emanuela Pilozzi; Francesco Carbonetti; Vincenzo David; Elsa Iannicelli
Journal:  J Gastrointest Cancer       Date:  2015-12

Review 4.  Hepatocellular Adenoma and Focal Nodular Hyperplasia.

Authors:  Taofic Mounajjed
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-05-01

Review 5.  [Overview: liver tumors].

Authors:  Ivo Graziadei
Journal:  Wien Med Wochenschr       Date:  2013-01-30

6.  Natural history of hepatocellular adenoma formation in glycogen storage disease type I.

Authors:  David Q Wang; Laurie M Fiske; Caroline T Carreras; David A Weinstein
Journal:  J Pediatr       Date:  2011-04-09       Impact factor: 4.406

7.  Appearance of hepatocellular adenomas on gadoxetic acid-enhanced MRI.

Authors:  Timm Denecke; Ingo G Steffen; Sheela Agarwal; Daniel Seehofer; Thomas Kröncke; Enrique Lopez Hänninen; Incken-Birthe Kramme; Peter Neuhaus; Sanjay Saini; Bernd Hamm; Christian Grieser
Journal:  Eur Radiol       Date:  2012-03-22       Impact factor: 5.315

Review 8.  Liver masses: a clinical, radiologic, and pathologic perspective.

Authors:  Sudhakar K Venkatesh; Vishal Chandan; Lewis R Roberts
Journal:  Clin Gastroenterol Hepatol       Date:  2013-09-18       Impact factor: 11.382

9.  Noncirrhotic hepatocellular carcinoma: derivation from hepatocellular adenoma? Clinicopathologic analysis.

Authors:  Ta-Chiang Liu; Neeta Vachharajani; William C Chapman; Elizabeth M Brunt
Journal:  Mod Pathol       Date:  2013-09-20       Impact factor: 7.842

10.  Management of hepatocellular adenoma: comparison of resection, embolization and observation.

Authors:  Ami M Karkar; Laura H Tang; Nilesh D Kashikar; Mithat Gonen; Stephen B Solomon; Ronald P Dematteo; Michael I D' Angelica; Camilo Correa-Gallego; William R Jarnagin; Yuman Fong; George I Getrajdman; Peter Allen; T Peter Kingham
Journal:  HPB (Oxford)       Date:  2012-10-09       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.